Tapinarof Cream 1% Once Daily for Plaque Psoriasis in Two Pivotal Phase 3 Trials: Minimal Systemic Exposure is Consistent With Adverse Event Profile
Recommended Citation
Stein Gold LF, Lebwohl MG, Brown PM, Rubenstein DS, Tabolt G, Jett JE, Piscitelli SC. Tapinarof Cream 1% Once Daily for Plaque Psoriasis in Two Pivotal Phase 3 Trials: Minimal Systemic Exposure is Consistent With Adverse Event Profile. J Am Acad Dermatol 2023; 89(3):AB229.
Document Type
Conference Proceeding
Publication Date
9-1-2023
Publication Title
J Am Acad Dermatol
Volume
89
Issue
3
First Page
AB229
COinS
